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Data regarding the efficacy and safety of methotrexate 
(MTX) in adults with localized scleroderma (LoS) is scar-
ce. This study gathered data from a retrospective cohort 
of adult patients with LoS (n = 107), treated with MTX 
(1993–2015). MTX drug survival and predictors thereof 
were analysed. After 1 and 2 years, 26% and 63% of pa-
tients stopped MTX due to disease remission, respective-
ly. Patients with younger age at MTX initiation (hazard 
ratio (HR) 1.159 (95% confidence interval (CI) 1.052–
1.277)) and those with no other autoimmune diseases (HR 
3.268 (95% CI 1.334–8.009)) more often stopped MTX 
due to disease remission. In addition, 24% of patients 
stopped MTX due to treatment failure within one year. 
Patients with circumscribed superficial LoS (HR 0.221 
(95% CI 0.081–0.601)) experienced treatment failure less 
often than those with other LoS subtypes. Finally, adding 
folic acid (HR 0.184 (95% CI 0.079–0.425)) and reducing 
treatment delay (HR 1.056 (95% CI 1.004–1.112)) could 
be the most important factors in minimizing MTX treat-
ment failure in LoS in clinical practice. Key words: locali-
zed scleroderma; morphoea; methotrexate, treatment.
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Localized scleroderma (LoS), also known as morphoea, 
encompasses a spectrum of rare diseases causing fibrosis 
of the skin and underlying tissues, such as fat, fascia and 
muscle (1). Local sclerosis can cause extensive morbi-
dity, such as joint contractures, limb length discrepancies 
and muscle weakness, due to active myositis or muscle 
atrophy (2). This extensive morbidity in combination 
with the disease, in general, has a significant impact on 
quality of life and requires adequate treatment (3, 4).
Methotrexate (MTX), with or without concomitant 
systemic corticosteroids, is recommended as the pri-
mary treatment option in patients with moderate to 
severe or treatment refractory disease (5–7). However, 
data regarding the efficacy and safety of MTX in adult 
patients with LoS is scarce; to date only 3 studies have 
reported original data regarding MTX treatment in 
adults with LoS (8–10). As MTX is the most prescribed 
systemic treatment for LoS, there is an urgent need for 
more evidence regarding treatment strategies. 
The main objective of this study was to describe drug 
survival for MTX treatment in a large long-term daily 
practice cohort of patients with LoS. Drug survival 
analyses allow evaluation of treatment duration with 
a particular drug with regards to different outcomes 
of interest. Drug survival is a comprehensive outcome 
covering effectiveness, safety, and patients’ and doctors’ 
preferences (11). We investigated the drug survival split 
for disease remission and treatment failure. In addition, 
by identifying predictors of drug survival for MTX we 
aimed to improve treatment strategies. 
METHODS
Patients and data collection
A retrospective chart review of adult patients with LoS treated 
with MTX was performed. All patients were evaluated at the 
combined dermatology and rheumatology outpatient clinic at 
Radboud University Medical Center (Nijmegen, The Nether-
lands) between August 1993 and July 2015. The first treatment 
episode with MTX was included for analysis. The following 
information was collected: age at treatment initiation, route 
of administration, dosage alterations, overall treatment dura-
tion and prescription of folic acid or concomitant systemic 
corticosteroids.
Reasons for treatment discontinuation
The first reason for treatment discontinuation was disease re-
mission, which was present if the treating physician reported 
a satisfactory result at treatment cessation. The second reason 
for treatment discontinuation was treatment failure, which, for 
subanalyses, was split into side-effects and treatment ineffec-
tiveness. Ineffectiveness was present if the treating physician 
reported an unsatisfactory treatment result. In addition, patients 
could be categorized as having a mixture of reasons for stopping 
treatment (i.e. side-effects and ineffectiveness). Finally, patients 
could be categorized as having another reason for stopping 
treatment (i.e. patient’s wish or elective surgery). 
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Predictors of drug survival
In order to understand the selection procedure for possible 
predictors, Cox-regression analyses allowed us to investigate 
associations between baseline variables and an outcome of in-
terest. Treatment-specific variables in this context are, however, 
confounded by indication and should not be analysed using this 
method. Therefore, we selected the following baseline characte-
ristics as candidate predictors: sex, age at disease onset, calendar 
year at MTX initiation, time between disease onset and MTX 
initiation (treatment initiation delay), disease subtype as reported 
by Laxer & Zulian (12), prescription of folic acid at MTX initia-
tion, presence of anti-nuclear antibodies (ANAs), and presence 
of concomitant autoimmune diseases. To investigate whether 
drug survival of MTX was influenced by treatment behaviour, 
calendar year at MTX initiation was added as a possible predictor. 
Statistical analysis
Descriptive statistics, including median and range for continu-
ous variables and percentages for categorical data, were used 
to explore baseline and patient characteristics. Drug survival 
analyses were performed using Kaplan–Meier curves for 
MTX drug survival related to treatment failure and split for 
side-effects and treatment ineffectiveness. For the purpose of 
visualization drug survival related to disease remission was 
displayed as one minus survival curves. Treatment episodes 
were censored for a particular survival analysis when patients 
were still being treated at data lock, were lost to follow-up, or 
discontinued MTX for a reason other than the reason of interest. 
An MTX treatment episode was considered discontinued when 
MTX was interrupted for more than 21 days. 
Potential predictors were selected using a univariate Cox 
regression model separately for each different discontinuation 
reason. Determinants with a p-value ≤ 0.2 were imported in a 
multivariate Cox regression model with backward selection. 
As a rule of thumb, multivariate Cox regression analyses allow 
us to import one predictor of interest per 10 events for the dis-
continuation reason of interest (11). If the number of possible 
predictors identified by univariate analyses exceeded the number 
of predictors allowed in a multivariate model, we selected the 
predictors with the strongest association based on p-values. 
Predictors are displayed as hazard ratios (HRs) with correspon-
ding 95% confidence intervals (CIs). Statistical analyses were 
performed using SPSS Statistics v.22 (IBM, Armonk, NY, USA).
RESULTS
Baseline characteristics
In total, 113 patients with LoS using MTX were iden-
tified. A total of 107 (94.7%) patients were included 
for drug survival analysis. The remaining 6 patients 
were excluded due to incomplete data regarding MTX 
treatment. Baseline characteristics of the 107 patients, 
77 females (72.0%) and 30 males (28.0%) (ratio 2.6:1), 
are shown in Table I. The median age at disease onset 
was 46 years (range 2–77 years). Subtype distribution 
is shown in Table I. 
Treatment characteristics
Details of the MTX treatment are summarized in Table 
II. The median age at MTX initiation was 49 years 
(range 18–78 years) and the median time between di-
sease onset and MTX initiation was 18 months (range 
3–429 months). The median MTX treatment duration 
was 49 weeks (range 4–261 weeks). In general, patients 
received MTX 15 mg/week (range 5.0–26.9 mg/week) 
during the treatment episode. The median maximum 
dose was 15 mg (range 5.0–30 mg). Finally, 37 (34.6%) 
patients were concomitantly treated with systemic cor-
ticosteroids and 78 (72.9%) patients received folic acid. 
Reasons for methotrexate discontinuation 
In 44 (41.1%) of 107 patients, disease remission was 
the sole reason to stop MTX. Side-effects or treatment 
ineffectiveness, with no other reason, was a reason 
to discontinue MTX treatment in 12 (11.2%) and 14 
(13.1%) patients, respectively. In total, 8 patients 
(7.5%) had a combination of stopping reasons: 4 
(3.7%) had a combination of disease remission and 
side-effects, and 4 (3.7%) experienced treatment inef-
fectiveness and side-effects. Side-effects severe enough 
to lead to MTX discontinuation were gastro-intestinal 
symptoms (n = 7, 6.5%), laboratory abnormalities 
(n = 7, 6.5%), consisting of 5 patients (4.7%) with signs 
of hepatotoxicity and 2 (1.9%) of haematotoxicity, 
Table I. Demographics and subtype distribution in 107 subjects 
with localized scleroderma (LoS) treated with methotrexate (MTX)
Characteristics
Adult 
n = 107
Female:male, n (ratio) 77:30 (2.6:1.0)
MTX initiation, age, years, median (range) 49 (18–78)
Onset of LoS, age, years, median (range) 46 (2–77)
Subtypes, n (%)
Circumscribed
Superficial 27 (25.2)
Deep 12 (11.2)
Linear
Trunk/limbs 18 (16.8)
Head 1 (0.9)
Generalized 33 (30.8)
Mixed 16 (15.0)
Table II. Treatment characteristics in 107 subjects with localized 
scleroderma treated with methotrexate (MTX). Delay in MTX 
initiation was measured as the time between disease onset and 
MTX initiation
Characteristics Adult n = 107
Age at MTX initiation, years, median (range) 49 (18:78)
Delay in MTX initiation, months, median (range) 18 (3:429)
Duration of MTX treatment, weeks, median (range) 49 (4:261)
Maximum MTX dose, mg/week, median (range) 15.0 (5.0:30.0)
Mean MTX dose, mg/week, median (range) 15.0 (5.0:26.9
Route of administration
Oral 90 (84.1)
Subcutaneous 2 (1.9)
Switcha 15 (14.0)
Systemic corticosteroids, n (%) 37 (34.6)
Folic acid, n (%) 78 (72.9)
aSwitch from oral to subcutaneous administration. Reason for switching were 
side-effects in 4 patients or lacking efficacy in the remaining 11 patients.
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fatigue (n = 3, 2.8%), pulmonary symptoms suspected 
of being related to MTX (n = 3), renal impairment 
(n = 1, 0.9%), depression (n = 1, 0.9%) and headache 
(n = 1, 0.9%). Finally, 12 (11.2%) patients were lost 
to follow-up, 13 (12.2%) were still being treated at 
data lock and 4 (3.7%) had other reasons for treatment 
discontinuation (i.e. patient’s wish, elective surgery). 
Drug survival of methotrexate
Fig. 1a shows the one minus drug survival curve for 
MTX related to disease remission. After 1 year, 25.3% 
of patients stopped MTX because of disease remission. 
After 2 years this proportion was 62.5%. The median 
time to discontinuation of MTX due to disease remis-
sion was 87 weeks. Fig. 1b shows drug survival related 
to treatment failure. After 1 and 2 years, drug survival 
related to treatment failure was 75.7% and 54.7%, 
respectively. Subanalyses of drug survival related to 
the separated discontinuation reasons adverse events 
and ineffectiveness showed no significant differences. 
Selection of candidate predictors of drug survival
Table SI1 displays the HRs and 95% CIs for the univa-
riate Cox regression analysis for all the variables tested. 
The variables with a p-value ≤ 0.2 in the univariate 
analysis were put into the multivariate model.
Predictors of drug survival in localized scleroderma: 
disease remission
Forty-eight patients discontinued MTX due to disease 
remission, which allowed us to add 5 predictors of 
interest in a multivariate model. Univariate analysis 
identified age at MTX initiation (p = 0.004, HR 1.144 
(95% CI 1.043–1.255), absence of other autoimmune 
diseases (p = 0.004, HR 3.636 (95% CI 1.153–8.696)), 
absence of deep LoS (p = 0.007, HR 5.155 (95% CI 
1.572–16.949), absence of administration of folic acid 
(p = 0.00, HR 5.051 (95% CI 2.660–9.615) and the 
calendar year of MTX initiation (p = 0.000, HR 0.859 
(95% CI 0.81–0.909) as possible predictors. Fig. 2 
shows the HRs and 95% CIs resulting from the multi-
variate analysis. The following 3 variables remained 
statistically significant in a multivariable model: the 
calendar year of MTX initiation was associated with 
a drug survival related to disease remission (HR 0.865 
(95% CI 0.814–0.919). In other words, more recent 
MTX initiation, measured as a more recent calendar 
year, was associated with decreased drug survival 
due to disease remission. More interestingly, patients 
who only had LoS showed better drug survival rela-
ted to disease remission compared with patients with 
Fig. 1. (a) Methotrexate (MTX) 
time to disease remission curves 
in 107 patients with localized 
scleroderma. (b) MTX survival 
curves related to treatment failure 
(black line) segregated into side-
effects (green line) and treatment 
ineffectiveness (grey line).
Fig. 2. Predictors of metho-
trexate (MTX) drug survival 
in 107 patients with localized 
scleroderma, segregated for 
treatment discontinuation 
reasons (a) disease remission 
and (b) treatment failure. 
Displayed are hazard ratios 
and their confidence intervals 
resulted from multivariate Cox 
regression analyses. The x-axis 
in panel a is a log-2 scale.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2411
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multiple autoimmune diseases (HR 3.268 (95% CI 
1.334–8.009)). Finally, younger age (up to 18 years of 
age) at MTX initiation was associated with increased 
drug survival related to disease remission (HR 1.159 
(95% CI 1.052–1.277)).
Predictors of drug survival: treatment failure
Thirty-four patients discontinued MTX due to treat-
ment failure, which allowed us to add 3 predictors of 
interest to the multivariate model. Univariate analysis 
identified the delay in treatment initiation (p = 0.079, 
HR 1.044 (95% CI 0.995–1.096), having circumscribed 
superficial LoS (p = 0.020, HR 0.370 (95% CI 0.160– 
0.854)) and receiving folic acid (p = 0.006, HR 0.368 
(95% CI 0.180–0.735)) as possible predictors. All 3 
predictors remained significant in the multivariable 
model, leading to the following HRs and their inter-
pretation: patients who received folic acid (HR 0.184 
(95% CI 0.079–0.425)) and patients with circumscribed 
superficial LoS (HR 0.221 (95% CI 0.081–0.601)) were 
protected against treatment failure. On the other hand, 
patients with a longer treatment initiation delay (HR 
1.056 (95% CI 1.004–1.112)) were at greater risk for 
treatment failure.
Subanalyses of MTX discontinuation due to side-
effects and treatment ineffectiveness were restricted 
to multivariable models with 2 predictors due to the 
relatively low number of events for these 2 stopping 
reasons separately (20 and 18 events, respectively). 
Receiving folic acid (HR 0.279 (95% CI 0.101–0.773)) 
protected against side-effects, whereas patients with a 
prolonged treatment initiation delay (HR 1.076 (95% 
CI 1.014–1.142)) were at greater risk of stopping due 
to side-effects. Patients with a longer treatment initia-
tion delay were also at greater risk of stopping MTX 
due to treatment ineffectiveness (HR 1.057 (95% CI 
1.000–1.117).
DISCUSSION
In this study 26% and 63% of patients stopped MTX 
due to disease remission after one and two years, re-
spectively. The median time to MTX discontinuation 
due to disease remission was 87 weeks. Drug survival 
related to treatment failure was 76% after one year. 
Thus, 24% of patients stopped MTX within one year 
because of side-effects or treatment ineffectiveness. 
It is difficult to compare these results with those of 
other studies, as the current study presents the first 
data regarding drug survival of MTX in LoS. Most 
previous studies describing MTX in LoS focus on a 
paediatric population (13–19). Only 3 original papers 
have described MTX as a treatment option in adult 
patients; Seyger et al. (8) reported a beneficial effect of 
MTX in 6 out of 9 patients after 24 weeks. Kreuter et 
al. (10) reported a beneficial effect of MTX in combi-
nation with pulsed intravenous methylprednisolone in 
14 out of 15 patients. Finally, Kroft et al. (9) reported 
remission rates of 51% and 73% for MTX mono- and 
combination therapy with prednisone in a cohort that 
contained sclerotic diseases other than LoS (49 with 
LoS, 5 with eosinophilic fasciitis, 2 scleroderma dia-
beticorum and 2 scleromyxoedema).
In contrast to publications on LoS studies, drug 
survival studies have been reported more frequently in 
other diseases. However, in most diseases, remission 
is not a reason to stop treatment. Shalom et al. (20) 
presented drug survival rates of MTX of only 59.3% 
after one year in 2,632 patients with psoriasis. Thus, 
40.7% of subjects stopped treatment within one year. 
However, the lack of detailed description of the reasons 
for discontinuation in this study means that it is difficult 
to compare this study with our results.
With regards to predictors of drug survival, we 
showed that younger age at treatment initiation was 
associated with higher rates of disease remission. A 
possible explanation could be that older patients are 
more frequently affected by comorbidities, which 
may lower the chance of treatment success. Secondly, 
not being affected by other autoimmune diseases also 
increased the chance of achieving disease remission. 
The group of patients with other autoimmune diseases 
might reflect a group of patients with more severe 
forms of the disease. Furthermore, we identified an 
association between calendar year at MTX initiation 
and disease remission. A possible explanation for this 
association could be changing prescription behaviour, 
as this analysis contains treatment episodes from the 
early 1990s. Treatment has become more aggressive 
during the years; partly due to increased experience with 
MTX and partly due to literature advocating prolonged 
treatment with MTX in LoS (18, 21). 
Regarding treatment failure, we show that folic 
acid protected against treatment failure (HR 0.184). 
The protective effect of folic acid against side-effects 
caused by MTX is well known in other diseases, such 
as rheumatic diseases and psoriasis (22–24). These 
findings, in combination with scarcity of alternative 
treatments for MTX in LoS, emphasize the necessity 
for the prescription of folic acid to decrease the likeli-
hood of MTX failure. Secondly, our results imply that 
more severe disease subtypes (i.e. the linear or deep 
subtypes) are more difficult to treat successfully, as 
the milder superficial subtype was associated with a 
lower risk of treatment failure compared with the severe 
subtypes. Most interestingly, we showed that patients 
with a longer delay in MTX initiation were at greater 
risk of stopping MTX due to treatment failure. These 
data suggest that early treatment, as is desired in other 
diseases, such as rheumatoid arthritis, is also preferred 
in LoS (25–27).
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A limitation of this study is its retrospective design. 
Secondly, the study is limited by the relatively low 
number of events, which prevented us from performing 
certain subgroup analyses. However, we maximized the 
number of candidate predictors for each multivariable 
model, based on the number of events in that model. 
Finally, we investigated associations between predictors 
and outcomes and not causality. Further replication of 
these data is needed to investigate causations between 
the predictors and outcomes identified in this study.
In conclusion, this is the first study to present data re-
garding drug survival and predictors for drug survival of 
MTX in adults with LoS in a large daily practice cohort. 
This study shows that 26% and 63% of patients stopped 
MTX due to disease remission after one and two years, 
respectively. Younger patients and those without other 
autoimmune diseases more frequently stopped MTX 
due to disease remission. In addition, 24% of patients 
stopped MTX due to treatment failure within one year. 
With regards to minimizing treatment failure, adding 
folic acid and a reduction in treatment delay might be 
the most important factors in clinical practice.
The authors declare no conflicts of interest.
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